Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via Google Scholar Articles by Shahzad, S. Articles by Lippmann, S. Search for Related Content PubMed Citation Articles by Shahzad, S. Articles by Lippmann, S. Atypical Neuroleptics Conventional Neuroleptics

Cataract Occurrence With Antipsychotic Drugs

Received Aug. 3, 2001; revision received Dec. 10, 2001; accepted Jan. 17, 2002. From the Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine. Address reprint requests to Dr. Lippmann, University of Louisville Hospital, 5 East, 530 South Jackson St., Louisville, KY 40202.

Chlorpromazine and several other phenothiazine neuroleptic drugs appear to induce cataract formation. However, the newer generation of antipsychotic agents has shown no evidence of an etiologic relationship with cataract occurrence. Research did reveal cataract occurrence in dogs who received quetiapine, which prompted concern despite there being no known causal link between quetiapine and lens opacities in humans. Nevertheless, quetiapine's manufacturer issued formal recommendations for ophthalmological follow-up examinations with the use of this drug. Infrequent occurrences of cataract development have been documented in people taking olanzapine but, again, without established causative association; a similar situation is seen with ziprasidone. Periodic ocular examinations of the lens are suggested for patients prescribed long-term treatment with phenothiazines or quetiapine.

Get information about faster international access.

Privacy Policy

Copyright © 2002 Academy of Psychosomatic Medicine. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us